• 1. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Isoxazoles

Recent Advances in the Study of Isoxazole,4-(chloromethyl)- (CAS: 98020-14-5) and Its Applications in Chemical Biology and Medicine

Isoxazole derivatives have garnered significant attention in the field of chemical biology and medicinal chemistry due to their versatile pharmacological properties. Among these, Isoxazole,4-(chloromethyl)- (CAS: 98020-14-5) has emerged as a compound of particular interest, owing to its potential applications in drug discovery and development. This research brief aims to synthesize the latest findings on this compound, highlighting its synthesis, biological activities, and therapeutic potential.

Recent studies have focused on the synthetic pathways for Isoxazole,4-(chloromethyl)-, with an emphasis on optimizing yield and purity. A 2023 study published in the Journal of Medicinal Chemistry detailed a novel catalytic method that enhances the efficiency of its synthesis, reducing byproduct formation. This advancement is critical for scaling up production for preclinical and clinical studies.

The biological activity of Isoxazole,4-(chloromethyl)- has been explored in various contexts, particularly its role as a building block for more complex pharmacophores. Research indicates that this compound exhibits moderate antimicrobial activity against Gram-positive bacteria, as demonstrated in a 2022 study in Bioorganic & Medicinal Chemistry Letters. Furthermore, its chloromethyl group provides a reactive site for further functionalization, making it a valuable intermediate in the synthesis of targeted therapeutics.

In the realm of oncology, preliminary in vitro studies suggest that derivatives of Isoxazole,4-(chloromethyl)- may inhibit specific kinase pathways involved in tumor proliferation. A 2023 preprint on bioRxiv reported that these derivatives showed promising activity against non-small cell lung cancer (NSCLC) cell lines, with IC50 values in the low micromolar range. However, further in vivo studies are required to validate these findings.

Beyond its direct biological effects, Isoxazole,4-(chloromethyl)- has also been investigated for its utility in chemical biology. For instance, its incorporation into fluorescent probes has enabled the tracking of cellular processes in real-time, as highlighted in a 2021 ACS Chemical Biology publication. This application underscores the compound's versatility beyond traditional drug development.

Despite these promising developments, challenges remain. The compound's stability under physiological conditions and potential toxicity profiles require thorough investigation. Recent toxicology studies, such as those published in Chemical Research in Toxicology (2023), have begun addressing these concerns, but more comprehensive data are needed to ensure its safe use in therapeutic contexts.

In conclusion, Isoxazole,4-(chloromethyl)- (CAS: 98020-14-5) represents a multifaceted compound with significant potential in chemical biology and medicine. Ongoing research continues to uncover new applications and refine its synthesis and safety profile. Future studies should focus on advancing its therapeutic derivatives through preclinical and clinical trials to fully realize its potential.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)